Biologic Therapy in Chronic Obstructive Pulmonary Disease.

Related Articles

Biologic Therapy in Chronic Obstructive Pulmonary Disease.

Immunol Allergy Clin North Am. 2017 May;37(2):345-355

Authors: Tripple JW, McCracken JL, Calhoun WJ

Abstract
Chronic obstructive pulmonary disease (COPD) is common worldwide. The predominant cause in most COPD is environmental exposure to toxicants. The inflammatory processes in COPD are multifactorial, complex, and interacting, leading to many potential therapeutic targets. Although most typically associated with neutrophilic/macrophagic inflammation (type 1), it is now known that COPD can also be associated with eosinophilic inflammation (type 2), particularly in exacerbations. Accordingly, there is an active program of investigation of highly selective biologic therapeutic agents in the management of COPD. This review summarizes clinical trials of the use of these novel agents in the management of COPD.

PMID: 28366481 [PubMed - in process]

http://ift.tt/2oGDcqx